F
papil loma vir us
(HPV). In fact, the
therapeutic vaccine
developed for HPV is
the first vaccine from
this BIIR-developed
platform of technologies to be produced
for potential use in
patients. The Scott &
W hite Healthcare
C a nc er R e se a rc h
Institute in Temple,
Texas, has a facility
capable of manufacCourtesy of Rockefeller University
turing the HPV vacDendritic cell cine for clinical trials
and will produce the vaccine over the next year. BIIR is currently
in the preclinical phase of manufacturing and safety testing in
animal models. Following the successful completion of that
phase, plans are to conduct a clinical trial of approximately 20
to 30 patients in 2016.
Baylor Health Care System Foundation provides hands-on
opportunities for philanthropic leaders to be involved in health
care initiatives that are changing North Texas and the world today.
By contributing to the Foundation, our donors support the discovery of preventive and therapeutic treatments that have the
opportunity to save lives, now and in the future.
C U S
O N
R E S E A R C H
“If these therapeutic vaccines work,
they will be a significant advance in
the treatment of HIV. ... We have more
research to do before these vaccines
move into standard patient care, but
we’re all very excited by the potential
that they offer.”
– Dr. L ouis Sloan
For more information on research initiatives at Baylor, contact
Sarah Burdi at 214.820.4721 or [email protected].
19
17